EML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies
Technology in Cancer Research & Treatment · 2026-06 · 25
DOI: 10.1177/15330338261457490 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 26.06.2026. Verfasst von Siqi Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Molecular Targeted Therapy, Oncogene Proteins, Fusion. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Scientific Research Foundation of the Science and Technology Department of Sichuan Province.
Abstract (Originalsprache)
Lung cancer is a malignancy characterized by high global incidence and mortality rates, with approximately 85% of cases classified as non-small cell lung cancer (NSCLC). Advances in molecular biology and targeted therapeutic agents have ushered NSCLC into the era of precision medicine. The echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) fusion gene represents a pivotal target for personalized treatment in NSCLC. Although ALK inhibitors exhibit significant efficacy against EML4-ALK-positive tumors, addressing drug resistance remains a major challenge. Identifying novel therapeutic targets and implementing combination therapies are essential for optimizing subsequent treatment strategies and improving overall prognosis. In the management of patients with EML4-ALK gene fusion, continuous monitoring of tumor progression and timely adjustment of treatment regimens based on disease status are critical to achieving long-term clinical benefits. This review comprehensively summarizes recent advances in the clinicopathological features, targeted drug development, resistance mechanisms, and potential therapeutic targets associated with the EML4-ALK fusion gene.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
- Department of Oncology, The General Hospital of Western Theater Command, Chengdu, Sichuan, China.
ORCID-Profile: Dong Li
Förderung
- The Scientific Research Foundation of the Science and Technology Department of Sichuan Province
Zitieren
APA
Li, S., Bao, L., Zhou, D., & Li, D. (2026). EML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261457490
Vancouver
Li S, Bao L, Zhou D, Li D. EML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261457490
BibTeX
@article{Li2026,
author = {Li, Siqi and Bao, Lingbo and Zhou, Daijun and Li, Dong},
title = {EML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
volume = {25},
doi = {10.1177/15330338261457490}
}
EUVIMED